We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
+$6.44M
Cap. Flow
-$803K
Cap. Flow %
-0.33%
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11

Top Buys

Rank Stock Value
1
BKCC
BlackRock Capital Investment Corporation
BKCC
+$673K
2
ZLAB icon
Zai Lab
ZLAB
+$472K
3
SCM icon
Stellus Capital Investment Corp
SCM
+$422K
4
DRD
DRDGold
DRD
+$415K
5
OXLC
Oxford Lane Capital
OXLC
+$359K

Top Sells

Rank Stock Value
1
AMRS
Amyris Inc.
AMRS
+$1.16M
2
RUBY
Rubius Therapeutics, Inc
RUBY
+$664K
3
BNTX icon
BioNTech
BNTX
+$663K
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$645K
5
PRTA icon
Prothena Corp
PRTA
+$590K

Sector Composition

Rank Sector Weight
1 Healthcare 27.38%
2 Real Estate 18.81%
3 Energy 13.29%
4 Materials 10.7%
5 Utilities 10.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRA icon
226
Atara Biotherapeutics
ATRA
$70.1M
$237K 0.1%
610
+99
+19% +$35.3K
BCAB icon
227
BioAtla
BCAB
$5.74M
$237K 0.1%
+112
New +$253K
CDXS icon
228
Codexis
CDXS
$141M
$235K 0.1%
10,385
-5,564
-35% -$121K
EPIX
229
DELISTED
ESSA Pharma
EPIX
$235K 0.1%
+8,233
New +$239K
KRYS icon
230
Krystal Biotech
KRYS
$9.97B
$235K 0.1%
3,455
-1,696
-33% -$118K
DNLI icon
231
Denali Therapeutics
DNLI
$3.77B
$234K 0.1%
2,980
-664
-18% -$41.1K
AMRS
232
DELISTED
Amyris Inc.
AMRS
$234K 0.1%
14,284
-77,973
-85% -$1.16M
RXDX
233
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$234K 0.1%
+9,519
New +$212K
MYOV
234
DELISTED
Myovant Sciences Ltd.
MYOV
$234K 0.1%
10,270
-2,187
-18% -$46K
ANAB icon
235
AnaptysBio
ANAB
$1.61B
$233K 0.1%
8,987
-3,489
-28% -$83.6K
INO icon
236
Inovio Pharmaceuticals
INO
$80M
$233K 0.1%
2,092
-312
-13% -$30K
AKBA icon
237
Akebia Therapeutics
AKBA
$341M
$232K 0.1%
61,284
-33,148
-35% -$112K
RGNX icon
238
Regenxbio
RGNX
$641M
$232K 0.1%
5,962
-1,516
-20% -$54.2K
VIR icon
239
Vir Biotechnology
VIR
$1.5B
$232K 0.1%
4,912
-4,302
-47% -$196K
KYNB
240
Kyntra Bio
KYNB
$28.4M
$231K 0.1%
347
+74
+27% +$42.6K
ALLO icon
241
Allogene Therapeutics
ALLO
$621M
$230K 0.09%
8,817
-1,904
-18% -$54.3K
ARDX icon
242
Ardelyx
ARDX
$1.26B
$229K 0.09%
30,187
-13,462
-31% -$99.5K
NVAX icon
243
Novavax
NVAX
$1.25B
$229K 0.09%
1,077
-1,231
-53% -$226K
SWTX
244
DELISTED
SpringWorks Therapeutics
SWTX
$229K 0.09%
2,774
-1,232
-31% -$93.5K
ALBO
245
DELISTED
Albireo Pharma Inc
ALBO
$229K 0.09%
6,523
-803
-11% -$26.1K
SRNE
246
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$229K 0.09%
23,646
-16,454
-41% -$131K
FMTX
247
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$229K 0.09%
9,220
+2,944
+47% +$79.1K
BCYC
248
Bicycle Therapeutics
BCYC
$273M
$228K 0.09%
+7,509
New +$227K
MGTX icon
249
MeiraGTx Holdings
MGTX
$1.14B
$228K 0.09%
14,736
-8,443
-36% -$121K
SGMO
250
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$228K 0.09%
19,037
-3,913
-17% -$44.3K
8 9
10
11 12

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q2 2021 Portfolio in Review

As of Q2 2021, Virtus ETF Advisers held 410 positions worth $243M, up 2.7% from $237M the previous quarter. Its ten largest holdings account for 7.7% of the portfolio.

Virtus ETF Advisers's Q2 2021 filing shows 55 new, 156 increased, 186 reduced and 11 closed positions. Its largest new stake was Zai Lab: 2,937 shares worth $520K. The largest sale was Amyris Inc., an estimated $1.16M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 30% a quarter earlier, followed by Real Estate and Energy.

  • Virtus ETF Advisers's largest Q2 2021 buy was Zai Lab: 2,937 shares worth $520K.
  • Virtus ETF Advisers added most to BlackRock Capital Investment Corporation in Q2 2021, an estimated $673K increase.
  • Virtus ETF Advisers's biggest Q2 2021 reduction was Amyris Inc., cutting an estimated $1.16M.
  • Virtus ETF Advisers fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $645K.
  • Virtus ETF Advisers's ten largest holdings make up 7.7% of its $243M portfolio in Q2 2021.
  • Virtus ETF Advisers opened 55 new positions and closed 11 in Q2 2021.
  • Virtus ETF Advisers's portfolio value rose 2.7% quarter-over-quarter to $243M.

Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.